105 related articles for article (PubMed ID: 9796990)
1. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy.
Dolman CS; Mueller BM; Lode HN; Xiang R; Gillies SD; Reisfeld RA
Clin Cancer Res; 1998 Oct; 4(10):2551-7. PubMed ID: 9796990
[TBL] [Abstract][Full Text] [Related]
2. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases.
Xiang R; Lode HN; Dreier T; Gillies SD; Reisfeld RA
Cancer Res; 1998 Sep; 58(17):3918-25. PubMed ID: 9731503
[TBL] [Abstract][Full Text] [Related]
3. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
[TBL] [Abstract][Full Text] [Related]
4. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
Eisenthal A; Cameron RB; Uppenkamp I; Rosenberg SA
Cancer Res; 1988 Dec; 48(24 Pt 1):7140-5. PubMed ID: 3263900
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
[TBL] [Abstract][Full Text] [Related]
6. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases.
Gillies SD; Lan Y; Wesolowski JS; Qian X; Reisfeld RA; Holden S; Super M; Lo KM
J Immunol; 1998 Jun; 160(12):6195-203. PubMed ID: 9637539
[TBL] [Abstract][Full Text] [Related]
7. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
[TBL] [Abstract][Full Text] [Related]
8. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
9. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer.
Wagner K; Schulz P; Scholz A; Wiedenmann B; Menrad A
Clin Cancer Res; 2008 Aug; 14(15):4951-60. PubMed ID: 18676770
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy.
Christ O; Seiter S; Matzku S; Burger C; Zöller M
Clin Cancer Res; 2001 Apr; 7(4):985-98. PubMed ID: 11309350
[TBL] [Abstract][Full Text] [Related]
12. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
13. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.
Xiang R; Lode HN; Dolman CS; Dreier T; Varki NM; Qian X; Lo KM; Lan Y; Super M; Gillies SD; Reisfeld RA
Cancer Res; 1997 Nov; 57(21):4948-55. PubMed ID: 9354462
[TBL] [Abstract][Full Text] [Related]
14. Human CD4+ effector T cells mediate indirect interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice.
Egilmez NK; Hess SD; Chen FA; Takita H; Conway TF; Bankert RB
Cancer Res; 2002 May; 62(9):2611-7. PubMed ID: 11980657
[TBL] [Abstract][Full Text] [Related]
15. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model.
Nasu Y; Bangma CH; Hull GW; Lee HM; Hu J; Wang J; McCurdy MA; Shimura S; Yang G; Timme TL; Thompson TC
Gene Ther; 1999 Mar; 6(3):338-49. PubMed ID: 10435084
[TBL] [Abstract][Full Text] [Related]
17. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
[TBL] [Abstract][Full Text] [Related]
18. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
19. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
